Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001628280-25-001065
Filing Date
2025-01-10
Accepted
2025-01-10 09:10:41
Documents
17
Period of Report
2024-10-31
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A lyel-20241031.htm   iXBRL 8-K/A 39483
2 EX-23.1 ex-231.htm EX-23.1 3054
3 EX-99.1 ex-991.htm EX-99.1 450949
4 EX-99.2 ex-992.htm EX-99.2 429993
5 EX-99.3 ex-993.htm EX-99.3 263743
  Complete submission text file 0001628280-25-001065.txt   1424813

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lyel-20241031.xsd EX-101.SCH 1776
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lyel-20241031_lab.xml EX-101.LAB 21629
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lyel-20241031_pre.xml EX-101.PRE 12504
19 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20241031_htm.xml XML 2727
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40502 | Film No.: 25520734
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)